Literature DB >> 3871951

Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor.

K Welte, E Platzer, L Lu, J L Gabrilove, E Levi, R Mertelsmann, M A Moore.   

Abstract

Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a protein that is constitutively produced by the human bladder carcinoma cell line 5637, has been purified from low serum (0.2% fetal calf serum)-containing conditioned medium. The purification involved sequential ammonium sulfate precipitation, ion-exchange chromatography, gel filtration, and reversed-phase high-performance liquid chromatography. The purified protein has a molecular weight of 18,000 in NaDodSO4/polyacrylamide gel electrophoresis, both by the silver staining technique and by elution of biological activity from a corresponding gel slice, and has an isoelectric point of 5.5. Pluripotent CSF supports the growth of human mixed colonies, granulocyte-macrophage colonies, and early erythroid colonies and induces differentiation of the human promyelocytic leukemic cell line HL-60 and the murine myelomonocytic leukemic cell line WEHI-3B (D+). The specific activity of the purified pluripotent CSF in the granulocyte-macrophage colony assay is 1.5 X 10(8) units/mg of protein.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871951      PMCID: PMC397296          DOI: 10.1073/pnas.82.5.1526

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  The selective enhancing influence of hemin and products of human erythrocytes on colony formation by human multipotential (CFUGEMM) and erythroid (BFUE) progenitor cells in vitro.

Authors:  L Lu; H E Broxmeyer
Journal:  Exp Hematol       Date:  1983-09       Impact factor: 3.084

2.  Characterization of stimulatory activity for human pluripotent stem cells (CFUGEMM).

Authors:  S Ruppert; G W Löhr; A A Fauser
Journal:  Exp Hematol       Date:  1983-02       Impact factor: 3.084

3.  Large-scale preparation and characterization of human colony-stimulating factor.

Authors:  T Okabe; H Nomura; N Sato; N Ohsawa
Journal:  J Cell Physiol       Date:  1982-01       Impact factor: 6.384

4.  Molecular cloning of cDNA for murine interleukin-3.

Authors:  M C Fung; A J Hapel; S Ymer; D R Cohen; R M Johnson; H D Campbell; I G Young
Journal:  Nature       Date:  1984 Jan 19-25       Impact factor: 49.962

5.  Stimulatory activity for human pluripotent hemopoietic progenitors produced by a human T-lymphocyte cell line.

Authors:  A A Fauser; H A Messner; A J Lusis; D W Golde
Journal:  Stem Cells       Date:  1981       Impact factor: 6.277

6.  Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity.

Authors:  K Welte; C Y Wang; R Mertelsmann; S Venuta; S P Feldman; M A Moore
Journal:  J Exp Med       Date:  1982-08-01       Impact factor: 14.307

7.  Structure-function studies of a colony stimulating factor (CSF-1).

Authors:  S K Das; E R Stanley
Journal:  J Biol Chem       Date:  1982-11-25       Impact factor: 5.157

8.  Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells. Identification as granulocyte colony-stimulating factor.

Authors:  N A Nicola; D Metcalf; M Matsumoto; G R Johnson
Journal:  J Biol Chem       Date:  1983-07-25       Impact factor: 5.157

9.  Procedures for the purification of interleukin 3 to homogeneity.

Authors:  J N Ihle; J Keller; L Henderson; F Klein; E Palaszynski
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

10.  Association of cell cycle expression of Ia-like antigenic determinations on normal human multipotential (CFU-GEMM) and erythroid (BFU-E) progenitor cells with regulation in vitro by acidic isoferritins.

Authors:  L Lu; H E Broxmeyer; P A Meyers; M A Moore; H T Thaler
Journal:  Blood       Date:  1983-02       Impact factor: 22.113

View more
  105 in total

Review 1.  G-CSF: status quo and new indications.

Authors:  F Herrmann
Journal:  Infection       Date:  1992 Jul-Aug       Impact factor: 3.553

2.  Recombinant filgrastim (BK0023) pharmacodynamics and pharmacokinetics after single and multiple escalating doses in an equivalence study in healthy men.

Authors:  Andrea F D Di Stefano; Gaia Spinetti; Antonio Rusca; Milko M Radicioni; Luca Loprete; Domenica M G Lamparelli; Jutta Michael Hepp; Davide Crobu; Rodolfo Schrepfer; Giancarlo Tonon
Journal:  Clin Drug Investig       Date:  2015-09       Impact factor: 2.859

3.  Registries for study of nonmalignant hematological diseases: the example of the Severe Chronic Neutropenia International Registry.

Authors:  David C Dale; Audrey Anna Bolyard; Laurie A Steele; Cornelia Zeidler; Karl Welte
Journal:  Curr Opin Hematol       Date:  2020-01       Impact factor: 3.284

Review 4.  Hematopoietic cytokines.

Authors:  Donald Metcalf
Journal:  Blood       Date:  2008-01-15       Impact factor: 22.113

5.  Differential effects of microenvironmentally presented interleukin 3 versus soluble growth factor on primitive human hematopoietic cells.

Authors:  T Otsuka; J D Thacker; C J Eaves; D E Hogge
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

Review 6.  Concise review: Sowing the seeds of a fruitful harvest: hematopoietic stem cell mobilization.

Authors:  Jonathan Hoggatt; Jennifer M Speth; Louis M Pelus
Journal:  Stem Cells       Date:  2013-12       Impact factor: 6.277

7.  Protective effects of recombinant human granulocyte colony stimulating factor in a rat model of necrotizing enterocolitis.

Authors:  Fuat Emre Canpolat; Murat Yurdakök; Sule Ozsoy; Rifki Haziroğlu; Ayşe Korkmaz
Journal:  Pediatr Surg Int       Date:  2006-07-27       Impact factor: 1.827

Review 8.  Recombinant methionyl granulocyte colony-stimulating factor (filgrastim): a new dimension in immunotherapy.

Authors:  G Schwab; T Hecht
Journal:  Ann Hematol       Date:  1994-07       Impact factor: 3.673

9.  Urinary bladder carcinoma producing granulocyte colony stimulating factor (G-CSF): a case report with immunohistochemistry.

Authors:  T Ito; K Shimamura; K Shoji; A Akatsuka; Y Kiryu; N Tamaoki; Y Osamura
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

10.  A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia.

Authors:  D C Dale; M A Bonilla; M W Davis; A M Nakanishi; W P Hammond; J Kurtzberg; W Wang; A Jakubowski; E Winton; P Lalezari
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.